1. Oral GS-5806 Activity in a Respiratory Syncytial Virus Challenge Study.
- Author
-
DeVincenzo, John P., Whitley, Richard J., Mackman, Richard L., Scaglioni-Weinlich, Cecilia, Harrison, Lisa, Farrell, Eric, McBride, Stephen, Lambkin-Williams, Robert, Jordan, Robert, Yan Xin, Ramanathan, Srini, O'Riordan, Thomas, Lewis, Sandra A., Xiaoming Li, Toback, Seth L., Shao-Lee Lin, and Chien, Jason W.
- Subjects
- *
VIRUS inhibitors , *RESPIRATORY syncytial virus infections , *INFANT mortality , *VIRAL load , *RANDOMIZED controlled trials , *THERAPEUTICS - Abstract
The article offers information on a randomized clinical trial conducted to observe the activity of GS-5806, which is an inhibitor of respiratory syncytial virus (RSV) that leads to infant hospitalizations, morbidity and mortality. It states that the participants were divided into two groups, one received GS-5806 and other received placebo. It concludes that the treatment of infants with GS-5806 reduced the viral load of RSV.
- Published
- 2014
- Full Text
- View/download PDF